IHAM
CYTK icon

Integral Health Asset Management’s Cytokinetics CYTK Stock Holding History

Integral Health Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136M Hold
1,600,000
– – 5.38% 3
2026
Q1 		$105M Buy
1,600,000
+200,000
+14% +$12.7M 5.04% 3
2025
Q4 		$89M Hold
1,400,000
– – 4.42% 4
2025
Q3 		$76.9M Buy
1,400,000
+400,000
+40% +$16.5M 5.21% 2
2025
Q2 		$33M Sell
1,000,000
-100,000
-9% -$3.48M 3.02% 6
2025
Q1 		$44.2M Buy
1,100,000
+100,000
+10% +$4.6M 4.7% 3
2024
Q4 		$47M Buy
1,000,000
+250,000
+33% +$13M 4.01% 5
2024
Q3 		$39.6M Sell
750,000
-250,000
-25% -$13.9M 4.46% 4
2024
Q2 		$54.2M Buy
1,000,000
+550,000
+122% +$33.2M 5.15% 3
2024
Q1 		$31.5M Buy
450,000
+250,000
+125% +$19.3M 2.93% 5
2023
Q4 		$16.7M Sell
200,000
-600,000
-75% -$21.7M 2.27% 10
2023
Q3 		$23.6M Buy
800,000
+150,000
+23% +$5M 3.26% 5
2023
Q2 		$21.2M Buy
650,000
+50,000
+8% +$1.85M 2.63% 7
2023
Q1 		$21.1M Buy
600,000
+200,000
+50% +$8.16M 4.25% 2
2022
Q4 		$18.3M Buy
400,000
+50,000
+14% +$2.15M 3.85% 2
2022
Q3 		$17M Sell
350,000
-175,000
-33% -$8.42M 3.29% 5
2022
Q2 		$20.6M Buy
525,000
+55,000
+12% +$2.21M 4.24% 4
2022
Q1 		$17.3M Buy
470,000
+145,000
+45% +$5.15M 4.5% 2
2021
Q4 		$14.8M Hold
325,000
– – 4.1% 3
2021
Q3 		$11.6M Sell
325,000
-375,000
-54% -$11M 3.34% 5
2021
Q2 		$13.9M Hold
700,000
– – 3.81% 4
2021
Q1 		$16.3M Buy
700,000
+175,000
+33% +$3.74M 4.65% 2
2020
Q4 		$10.9M Buy
525,000
+325,000
+163% +$5.94M 3.25% 8
2020
Q3 		$4.33M Sell
200,000
-140,000
-41% -$3.27M 1.32% 26
2020
Q2 		$8.01M Buy
340,000
+20,000
+6% +$375K 2.4% 14
2020
Q1 		$3.77M Buy
+320,000
New +$4.08M 1.66% 24

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Integral Health Asset Management's CYTK Position: Q2 2026 in Review

Integral Health Asset Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 1,600,000 shares worth $136M. The position accounts for 5.38% of the portfolio, ranked #3.

Integral Health Asset Management first reported a position in CYTK in Q1 2020 and has held it in 26 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Integral Health Asset Management held 1,600,000 shares of Cytokinetics worth $136M as of Q2 2026.
  • Integral Health Asset Management left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up 5.38% of Integral Health Asset Management's portfolio in Q2 2026, its #3 holding.
  • Integral Health Asset Management first reported a position in Cytokinetics in Q1 2020 and has held it in 26 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.